Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer.
chemotherapy
germ cell tumors
immunity
inflammation markers
prognostic factors
testicular cancer (GCT)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
03
2022
accepted:
26
04
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Germ cell tumors are the most common malignant tumors in male young adults. Platinum-based chemotherapy has dramatically improved the outcome of metastatic germ cell tumor patients and overall cure rates now exceed 80%. The choice of medical treatment can be guided by the prognosis estimation which is an important step during the decision-making process. IGCCCG classification plays a pivotal role in the management of advanced disease. However, histological and clinical parameters are the available factors that condition the prognosis, but they do not reflect the tumor's molecular and pathological features and do not predict who will respond to chemotherapy. After first-line chemotherapy 20%-30% of patients relapse and for these patients, the issue of prognostic factors is far more complex. Validated biomarkers and a molecular selection of patients that reflect the pathogenesis are highly needed. The association between cancer-related systemic inflammation, tumorigenesis, and cancer progression has been demonstrated. In the last years, several studies have shown the prognostic utility of immune-inflammation indexes in different tumor types. This review analyzed the prognostic impact of inflammatory markers retrieved from routine blood draws in GCT patients.
Identifiants
pubmed: 35756636
doi: 10.3389/fonc.2022.910087
pmc: PMC9226315
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
910087Informations de copyright
Copyright © 2022 Bleve, Cursano, Casadei, Schepisi, Menna, Urbini, Gianni, De Padova, Filograna, Gallà, Rosti, Barone, Chovanec, Mego and De Giorgi.
Déclaration de conflit d'intérêts
UD received speaker honoraria or travel support from Astellas, Janssen-Cilag, and Sanofi-Aventis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Urol. 2010 Apr;57(4):679-87
pubmed: 19560254
J Clin Oncol. 1998 Jul;16(7):2500-4
pubmed: 9667270
Oncotarget. 2016 Dec 20;7(51):85641-85649
pubmed: 27821802
J Clin Oncol. 1998 Apr;16(4):1287-93
pubmed: 9552027
Ann Oncol. 2014 May;25(5):987-91
pubmed: 24595454
Clin Genitourin Cancer. 2017 Jun;15(3):411-416.e2
pubmed: 28237180
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
J Clin Oncol. 2021 May 10;39(14):1563-1574
pubmed: 33822655
Front Endocrinol (Lausanne). 2019 Apr 12;10:218
pubmed: 31031704
Nat Rev Cancer. 2005 Mar;5(3):210-22
pubmed: 15738984
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Rare Tumors. 2017 Jul 03;9(2):6867
pubmed: 28975019
Ann Oncol. 2005 Jan;16(1):146-51
pubmed: 15598952
Sci Rep. 2017 Dec 7;7(1):17166
pubmed: 29215037
J Clin Oncol. 2019 Jun 1;37(16):1412-1423
pubmed: 30875280
In Vivo. 2006 Nov-Dec;20(6A):697-701
pubmed: 17203748
Clin Breast Cancer. 2012 Aug;12(4):264-9
pubmed: 22591634
Future Oncol. 2019 Feb;15(5):533-541
pubmed: 30624089
Int Braz J Urol. 2020 Jan-Feb;46(1):101-107
pubmed: 31851466
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Ann Oncol. 2016 Feb;27(2):300-5
pubmed: 26598537
Bone Marrow Transplant. 2003 Sep;32(5):489-94
pubmed: 12942095
PLoS One. 2011 Apr 21;6(4):e19198
pubmed: 21532991
Front Immunol. 2021 Aug 27;12:721989
pubmed: 34512646
Nat Rev Urol. 2018 Mar;15(3):137
pubmed: 29297888
Nat Rev Urol. 2016 Dec;13(12):715-725
pubmed: 27754472
Br J Cancer. 2018 Mar 20;118(6):831-838
pubmed: 29485980
Oncoimmunology. 2017 Mar 20;6(4):e1305535
pubmed: 28507813
Int J Clin Oncol. 2018 Feb;23(1):104-113
pubmed: 28951992
Ann Surg Treat Res. 2014 Jun;86(6):309-13
pubmed: 24949322
Onco Targets Ther. 2019 Apr 03;12:2505-2512
pubmed: 31040693
Cancer. 2017 Jun 15;123(12):2190-2192
pubmed: 28513824
N Engl J Med. 1990 Nov 1;323(18):1228-33
pubmed: 2215606
Mol Aspects Med. 2015 Nov;45:28-36
pubmed: 25936279
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Ann Oncol. 2008 Feb;19(2):259-64
pubmed: 18042838
Cell Commun Signal. 2015 Feb 27;13:14
pubmed: 25889536
Turk J Urol. 2017 Mar;43(1):55-61
pubmed: 28270952
Eur J Cancer. 2017 May;76:1-7
pubmed: 28262583
Oncotarget. 2016 Aug 23;7(34):54564-54571
pubmed: 27409344
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1302-1310
pubmed: 33629300
Transl Oncol. 2017 Oct;10(5):719-725
pubmed: 28710916
J Clin Oncol. 2010 Nov 20;28(33):4906-11
pubmed: 20956623
Urologia. 2021 Aug;88(3):200-205
pubmed: 33568012
Dig Surg. 2010;27(4):285-90
pubmed: 20689289
Br J Cancer. 2006 Jan 30;94(2):227-30
pubmed: 16404432
J Clin Oncol. 1998 Feb;16(2):702-6
pubmed: 9469360
Curr Oncol. 2020 Dec 21;28(1):107-114
pubmed: 33622996
J Biomed Res. 2013 Jul;27(4):254-71
pubmed: 23885265
J Clin Oncol. 2011 Jun 1;29(16):2178-84
pubmed: 21444870
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Andrology. 2020 Sep;8(5):1233-1242
pubmed: 32384200
Br J Cancer. 2013 Jul 23;109(2):401-7
pubmed: 23820256
Eur Urol. 2006 Nov;50(5):1032-8; discussion 1038-9
pubmed: 16757095
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817109
Mol Carcinog. 1995 Mar;12(3):124-31
pubmed: 7893365
Anticancer Res. 2021 Nov;41(11):5749-5759
pubmed: 34732448
Actas Urol Esp (Engl Ed). 2019 Jul - Aug;43(6):284-292
pubmed: 31085041
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Ann Surg Oncol. 2015 Apr;22(4):1377-84
pubmed: 25234022
Front Oncol. 2020 Aug 14;10:1325
pubmed: 32923384
Investig Clin Urol. 2021 Jan;62(1):47-55
pubmed: 33314803
Asian Pac J Cancer Prev. 2014;15(8):3369-75
pubmed: 24870724
Am J Clin Pathol. 2020 Feb 8;153(3):387-395
pubmed: 31802108
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
Clin Genitourin Cancer. 2017 Oct;15(5):e855-e857
pubmed: 28465048
Ann Oncol. 2017 Aug 01;28(8):1910-1916
pubmed: 28510616
Ann Oncol. 2018 Jan 1;29(1):209-214
pubmed: 29045540
Oncologist. 2019 Apr;24(4):e142-e145
pubmed: 30659078
Br J Cancer. 2018 Mar 20;118(6):825-830
pubmed: 29485982
Oncotarget. 2017 Mar 28;8(13):21794-21805
pubmed: 28423520
Bratisl Lek Listy. 2017;118(9):510-512
pubmed: 29061055
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Front Oncol. 2020 Sep 24;10:573977
pubmed: 33072608
Investig Clin Urol. 2019 May;60(3):176-183
pubmed: 31098425
Br Med Bull. 2010;93:85-103
pubmed: 19900948
Invest New Drugs. 2019 Aug;37(4):748-754
pubmed: 31152292
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
J Clin Oncol. 2010 Apr 1;28(10):1706-13
pubmed: 20194867
Int J Cancer. 1999 May 17;81(4):620-8
pubmed: 10225454
Br J Cancer. 2015 Jul 28;113(3):411-3
pubmed: 26171934
Cancers (Basel). 2019 Oct 11;11(10):
pubmed: 31614500
J Clin Oncol. 2021 May 10;39(14):1553-1562
pubmed: 33729863
J Clin Oncol. 2007 Jan 1;25(1):85-90
pubmed: 17194908
Cancer. 2003 Apr 15;97(8):1869-75
pubmed: 12673712
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560427
Cells. 2019 Dec 14;8(12):
pubmed: 31847394
Cancer Immunol Res. 2016 Nov;4(11):903-909
pubmed: 27638840
Crit Rev Oncol Hematol. 2016 May;101:213-20
pubmed: 27051042
Cancer Cell Int. 2020 Jun 09;20:224
pubmed: 32528232
Eur J Cancer. 2010 Dec;46(18):3425-33
pubmed: 20832295
Int J Urol. 2013 Feb;20(2):161-71
pubmed: 22897628
Clin Genitourin Cancer. 2019 Feb;17(1):e176-e183
pubmed: 30497810
J Clin Oncol. 1997 May;15(5):1844-52
pubmed: 9164194
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
J Clin Oncol. 2016 Feb 1;34(4):345-51
pubmed: 26460295
Crit Rev Oncol Hematol. 2005 Feb;53(2):141-64
pubmed: 15661565
Front Oncol. 2021 Mar 11;11:537140
pubmed: 33777726